Hormone replacement therapy and lipid-lipoprotein concentrations.

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Health
• Women's Health

Background:

• Menopause is associated with changes in lipid profiles, increasing cardiovascular risk.
• Hormone replacement therapy (HRT) is a common intervention for menopausal symptoms.
• Understanding HRT's impact on lipids is crucial for cardiovascular disease prevention.

Purpose of the Study:

• To investigate the association between HRT and lipid-lipoprotein concentrations in postmenopausal women.
• To compare the effects of different HRT formulations on lipid profiles.
• To evaluate long-term lipid changes over seven years of HRT.

Main Methods:

• An open prospective longitudinal study involving 6416 postmenopausal women.
• Participants received either estrogen-only therapy (conjugated equine estrogen [CEE] or transdermal estradiol [TDE2]) or combined estrogen-progestin therapy.
• Lipid-lipoprotein concentrations (total cholesterol, triglycerides, HDL-C, LDL-C, VLDL-C) were measured annually and cumulatively.

Main Results:

• Estrogen-only therapy significantly decreased total cholesterol, LDL-C, and VLDL-C, while increasing HDL-C.
• Transdermal estradiol (TDE2) showed a less pronounced increase in HDL-C and triglycerides compared to CEE.
• Combined estrogen-progestin therapy generally improved lipid profiles, with some formulations showing decreased triglycerides and VLDL.

Conclusions:

• Both estrogen-only and combined HRT formulations lead to more favorable lipid profiles in postmenopausal women.
• HRT can be an effective strategy for managing dyslipidemia in menopausal women.
• The choice of HRT formulation may influence the extent of lipid profile modification.